

Dave Sprengers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9230915/publications.pdf>

Version: 2024-02-01

56
papers

2,690
citations

201674

27
h-index

189892

50
g-index

56
all docs

56
docs citations

56
times ranked

4353
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2017, 153, 1107-1119.e10.	1.3	309
2	Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. <i>Hepatology</i> , 2004, 40, 738-746.	7.3	224
3	Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. <i>Antiviral Research</i> , 2015, 123, 120-131.	4.1	156
4	Activated tumor-infiltrating CD4 ⁺ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. <i>Hepatology</i> , 2013, 57, 183-194.	7.3	147
5	Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. <i>Journal of Hepatology</i> , 2015, 63, 1156-1163.	3.7	117
6	PD-L1, Galectin-9 and CD8 ⁺ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1273309.	4.6	117
7	Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 407-431.	4.5	103
8	TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 699895.	4.8	102
9	Î±-Galactosylceramide in Chronic Hepatitis B Infection: Results from a Randomized Placebo-Controlled Phase I/II Trial. <i>Antiviral Therapy</i> , 2009, 14, 809-818.	1.0	81
10	Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. <i>Journal of Hepatology</i> , 2019, 71, 753-762.	3.7	81
11	Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. <i>Oncolmmunology</i> , 2015, 4, e1008355.	4.6	78
12	Multiple biopsy passes and the risk of complications of percutaneous liver biopsy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 36-41.	1.6	65
13	Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2834-2848.	3.2	64
14	Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. <i>Hepatology</i> , 2006, 44, 907-914.	7.3	60
15	Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. <i>Cells</i> , 2020, 9, 121.	4.1	60
16	Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 352-359.	1.6	56
17	IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-Î±-stimulated genes. <i>FASEB Journal</i> , 2016, 30, 3352-3367.	0.5	54
18	Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1448332.	4.6	54

#	ARTICLE	IF	CITATIONS
19	Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. <i>Antiviral Research</i> , 2016, 133, 41-49.	4.1	50
20	LGR5 marks targetable tumor-initiating cells in mouse liver cancer. <i>Nature Communications</i> , 2020, 11, 1961.	12.8	49
21	GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells <i>ex vivo</i> . <i>Oncolmmunology</i> , 2015, 4, e1051297.	4.6	45
22	TIGIT and PD1 Co-blockade Restores <i>ex vivo</i> Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 443-464.	4.5	43
23	Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. <i>Journal of Hepatology</i> , 2006, 45, 182-189.	3.7	42
24	GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1111-1124.	5.1	42
25	Dynamics of Proliferative and Quiescent Stem Cells in Liver Homeostasis and Injury. <i>Gastroenterology</i> , 2017, 153, 1133-1147.	1.3	39
26	Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β -Catenin Signaling. <i>Neoplasia</i> , 2016, 18, 711-723.	5.3	37
27	Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis. <i>British Journal of Cancer</i> , 2020, 123, 196-206.	6.4	35
28	An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 1141-1157.	3.4	33
29	Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. <i>Carcinogenesis</i> , 2019, 40, 145-154.	2.8	30
30	HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis. <i>British Journal of Cancer</i> , 2020, 122, 1211-1218.	6.4	26
31	Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 15193-15204.	1.8	25
32	Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon- α Therapy for Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 1087-1096.	1.0	25
33	Evidence of good prognosis of hepatocellular adenoma in post-menopausal women. <i>Journal of Hepatology</i> , 2016, 65, 1163-1170.	3.7	23
34	Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. <i>British Journal of Cancer</i> , 2022, 127, 649-660.	6.4	23
35	Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. <i>Antiviral Research</i> , 2015, 124, 11-19.	4.1	22
36	Suppression of Hepatocellular Carcinoma by Mycophenolic Acid in Experimental Models and in Patients. <i>Transplantation</i> , 2019, 103, 929-937.	1.0	16

#	ARTICLE	IF	CITATIONS
37	Differential Sensitivities of Fast- and Slow-Cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid. <i>Molecular Medicine</i> , 2015, 21, 792-802.	4.4	14
38	Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 955-962.	1.6	14
39	Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. <i>British Journal of Cancer</i> , 2021, , .	6.4	12
40	Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies. <i>Journal of Virological Methods</i> , 2007, 142, 189-197.	2.1	11
41	Safety and Efficacy of ¹⁶⁶ Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1891-1898.	5.0	11
42	T-cell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment. <i>Oncoimmunology</i> , 2013, 2, e22450.	4.6	10
43	Multipotent mesenchymal stromal cells in liver cancer: Implications for tumor biology and therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 439-445.	7.4	10
44	Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. <i>BMJ Open</i> , 2018, 8, e020731.	1.9	10
45	Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma. <i>Translational Oncology</i> , 2021, 14, 101073.	3.7	10
46	Distinct Requirements for CD1d Intracellular Transport for Development of V α 14 iNKT Cells. <i>Journal of Immunology</i> , 2009, 183, 1780-1788.	0.8	9
47	Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2019, 40, 155-163.	2.8	9
48	To target or not to target viral antigens in HBV related HCC?. <i>Journal of Hepatology</i> , 2015, 62, 1449-1450.	3.7	6
49	Short article. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 963-966.	1.6	6
50	HLA matching and rabbit antithymocyte globulin as induction therapy to avoid multiple forms of rejection after a third liver transplantation. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101539.	1.5	5
51	Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infections. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1444-1451.	1.6	5
52	External Validation of the RETREAT Score for Prediction of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2022, 14, 630.	3.7	5
53	Histopathological growth patterns modify the prognostic impact of microvascular invasion in non-cirrhotic hepatocellular carcinoma. <i>Hpb</i> , 2021, , .	0.3	4
54	Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 615691.	2.8	3

#	ARTICLE	IF	CITATIONS
55	Coarse vs. fine needle aspiration biopsy. <i>Journal of Hepatology</i> , 2004, 41, 503-504.	3.7	2
56	Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study. <i>European Journal of Internal Medicine</i> , 2022, 97, 56-61.	2.2	1